Janet Woodcock’s tenure as director of the US Food and Drug Administration’s Center for Drug Evaluation and Research ended only three years ago, but some in Congress already are nostalgic for what they characterized as a bygone era.
Woodcock Nostalgia: GOP Rep. Bilirakis Wants CDER To Recapture Her Flexible Approach
Energy and Commerce Committee member suggests CBER now is more flexible with rare disease product approval requirements than CDER, inviting the drug center to return to its approach under former director Janet Woodcock.
More from Rare Diseases
More from Pink Sheet
• By
Pink Sheet reporter and editors discuss how staff may not be the only thing the FDA could lose with the latest layoffs announced by the Health and Human Services Department.
• By
The European Medicines Agency has recommended five drugs for EU-wide approval , including Averoa’s Xoanacyl for concomitant hyperphosphatemia. Two companies have withdrawn their marketing authorization applications.
• By
Eli Lilly’ will request a re-examination after the European Medicines Agency declined to recommend its Alzheimer’s disease drug Kisunla for EU approval.